Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. reported strong financial results for Q3 2026 (period ending December 31, 2025). The company generated total revenue of $31.6 million, with gross profit of $13.0 million and net income of $18.6 million. A significant driver of profitability was an $11.8 million non-cash gain from the change in fair value of derivative financial instruments - warrants. Operating income was $9.0 million, supported by total operating expenses of $3.9 million. The company maintained a solid balance sheet with total assets of $126.4 million, including $96.8 million in current assets and $21.1 million in cash. Total liabilities stood at $46.1 million, resulting in shareholders' equity of $80.3 million. Cash flow from operations was positive at $14.6 million, while investing activities used $528,000 and financing activities used $4.3 million, resulting in a net increase in cash and restricted cash of $9.8 million. The company's performance reflects continued operational strength, though the significant warrant valuation gain represents a non-operating item that contributed substantially to net income.

Key Takeaways